Search results
Showing 136 to 150 of 219 results for lower back pain
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.
Percutaneous intradiscal electrothermal therapy for low back pain (IPG319)
Interventional procedures, IPG319 - Issued: November 2009 --> This guidance has been updated and replaced by NICE interventional procedure guidance 544.
cohort of people who have a diagnosis of non-specific back pain who first consulted their GP for back symptoms...
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .
Lateral interbody fusion in the lumbar spine for low back pain (IPG574)
We have moved interventional procedures guidance 574 to become HealthTech guidance 431. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Non-rigid stabilisation techniques for the treatment of low back pain (IPG366)
Interventional procedures, IPG366 - Issued: November 2010 --> We have moved interventional procedures guidance 366 to become HealthTech guidance 239. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Percutaneous coblation of the intervertebral disc for low back pain and sciatica (IPG543)
We have moved interventional procedures guidance 543 to become HealthTech guidance 397. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Non-rigid stabilisation techniques for the treatment of low back pain (IPG183)
This guidance has been updated and replaced by NICE HealthTech guidance 239.
Peripheral nerve-field stimulation for chronic low back pain (IPG451)
Interventional procedures, IPG451 - Issued: March 2013 --> We have moved interventional procedures guidance 451 to become HealthTech guidance 309. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.